Solesence (SLSN)
NASDAQ:SLSN
Want to see SLSN full AI Analyst Report?
SLSN Stock Chart & Stats
$2.17
--
Market closed
$2.17
--
Day’s Range― - ―
52-Week Range$0.78 - $5.63
Previous CloseN/A
VolumeN/A
Average Volume (3M)50.43K
Market Cap
$85.47M
Enterprise Value$121.21M
Total Cash (Recent Filing)$1.29M
Total Debt (Recent Filing)$24.32M
Price to Earnings (P/E)62.9
Beta1.75
Next Earnings
May 13, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)<0.01
Shares Outstanding70,632,450
10 Day Avg. Volume39,901
30 Day Avg. Volume50,427
Financial Highlights & Ratios
PEG Ratio-1.10
Price to Book (P/B)6.38
Price to Sales (P/S)1.81
P/FCF Ratio-10.51
Enterprise Value/Market Cap1.42
Enterprise Value/Revenue1.95
Enterprise Value/Gross Profit7.55
Enterprise Value/Ebitda32.84
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Sustained Revenue GrowthRecord 2025 revenue and an 18.6% increase reflect durable commercial traction and successful customer wins. Over time, growing top-line driven by a large-scale launch and 20 new brand partners supports higher operating leverage, broadens customer relationships, and improves bargaining power with larger CPG customers.
Manufacturing Scale And ConsolidationFacility consolidation that maintains OTIF and claims >$200M capacity creates structural cost advantages and high incremental margins on future growth. Reduced fixed-cost base and six‑figure annual savings improve margin sustainability and lower future capex needs, enabling scalable growth without proportionate capital spend.
Expanding IP And Product RecognitionA growing patent portfolio and award recognition provide durable differentiation in specialty ingredients, supporting stickier customer relationships and potential pricing power. Proprietary technology raises barriers to entry, helps defend margins, and underpins product expansion into adjacent personal-care categories over the medium term.
Bears Say
Weak Cash GenerationPersistent negative free cash flow and a sharp 2025 cash burn signal cash-conversion issues driven by working capital and yield losses. Over months, weak cash generation raises refinancing and liquidity risk, constrains reinvestment capacity, and increases reliance on external capital which can dilute or restrict strategic options.
Margin Compression & Volatile ProfitabilityDeclining gross and net margins reflect operational inefficiencies, launch-related quality costs, and price/cost pressure. Margin volatility undermines durable earnings quality and makes achieving management's mid-term EBITDA targets harder, reducing ability to consistently self-fund growth or build reserves against future downturns.
Customer/ordering Concentration RiskDeclining open orders and reported weak sell-through at a major customer indicate customer concentration and demand volatility. Reliance on a few large buyers increases revenue sensitivity to client buy patterns, elevating execution and forecasting risk and making sustained growth and cash predictability more uncertain.
Solesence News
SLSN FAQ
What was Solesence’s price range in the past 12 months?
Solesence lowest stock price was $0.78 and its highest was $5.63 in the past 12 months.
What is Solesence’s market cap?
Solesence’s market cap is $85.47M.
When is Solesence’s upcoming earnings report date?
Solesence’s upcoming earnings report date is May 13, 2026 which is in 15 days.
How were Solesence’s earnings last quarter?
Solesence released its earnings results on Mar 31, 2026. The company reported $0.002 earnings per share for the quarter, beating the consensus estimate of N/A by $0.002.
Is Solesence overvalued?
According to Wall Street analysts Solesence’s price is currently Overvalued.
Does Solesence pay dividends?
Solesence does not currently pay dividends.
What is Solesence’s EPS estimate?
Solesence’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Solesence have?
Solesence has 70,632,450 shares outstanding.
What happened to Solesence’s price movement after its last earnings report?
Solesence reported an EPS of $0.002 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 5.333%.
Which hedge fund is a major shareholder of Solesence?
Currently, no hedge funds are holding shares in SLSN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Solesence Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-25.00%
12-Months-Change
Fundamentals
Return on Equity
10.50%
Trailing 12-Months
Asset Growth
0.11%
Trailing 12-Months
Company Description
Solesence
Solesence (SLSN) is a biotechnology company focused on developing innovative solutions for the cosmetics and personal care industries. The company specializes in harnessing the power of natural ingredients to create advanced formulations that enhance the performance and sensory attributes of beauty products. With a strong emphasis on sustainability and efficacy, Solesence serves a diverse range of clients, including leading beauty brands and manufacturers, by providing proprietary technology and products that improve product stability, texture, and delivery of active ingredients.
SLSN Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presents a balanced picture: strong commercial momentum with record revenue (+18.6%), expanded IP (patents +20%) and operational consolidation enabling future scale, but meaningful short-term profitability and operational execution issues constrained gross profit and adjusted EBITDA (~6.8%). Management has a clear corrective plan (Transform and Transcend) with concrete margin and EBITDA targets, yet near-term headwinds (inventory/yield losses, customer sell-through weakness, restructuring costs) temper the outlook.View all SLSN earnings summariesTechnical Analysis
Helen Of Troy
―
Nu Skin
―
Edgewell Personal Care
―
Beauty Health
―
European Wax Center
―
Ownership Overview
76.99% Insiders
2.00% Mutual Funds
0.05% Other Institutional Investors
18.88% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---